Ginger M. More

Ginger M.
More is currently a Special Limited Partner of Oak Investment Partners (“Oak”) and had been a General Partner or Managing Member since 1980.
Oak has raised ten venture capital partnerships with a total of $4.2 billion in committed capital.
Oak has sponsored over 350 companies with aggregate annual revenues in excess of $100 billion.
Oak’s most recent fund, Oak X, was closed on February 28, 2001 with a total capitalization of $1.6 billion.
Ginger joined Oak at its inception in 1978 after ten years at Wright Investor's Service.
She has sponsored investments in and/or served on the boards of numerous healthcare and information technology companies including the following publicly-traded companies, Alexion Pharmaceuticals, Inc., Alkermes, Inc., Compaq Computer Corporation, Dyax Corporation, Esperion Therapeutics, Inc., Genzyme Corporation, Octel Communications Corporation, OraPharma, Inc., Osteotech Inc., Pharmacopeia, Inc. and Ribozyme Pharmaceuticals, Inc. Ginger studied Mathematics at the University of Bridgeport and became a Chartered Financial Analyst in 1978.